Objectives and design: A vaccine capable of providing cross-clade, sterilizing protection has been the holy grail of HIV-1 prevention and control since the beginning of the pandemic. A major component of this effort has been the identification and characterization of broadly neutralizing antibodies (bNAbs). Recent advances in bNAb isolation, structure-based engineering, and vector-mediated gene transfer have led to increased interest in bypassing the immune system by expressing neutralizing antibodies directly in muscle. To assess the neutralization potency and coverage of a panel of second-generation bNAbs, we cloned and phenotypically characterized 227 primary HIV-1 envelopes from 23 mother-to-child transmission (MTCT) pairs.
Introduction
Despite three decades of effort, we still do not have a universal HIV-1 vaccine, and it will be difficult to fully control the pandemic without one. Most chronically HIV-infected individuals, and most vaccine immunogens tested to date, produce a somewhat narrow, strain-specific response that does not afford significant protection against heterologous challenge [1] [2] [3] . Fortunately, some chronically HIV-infected individuals do eventually produce an antibody response with the cross-clade activity desirable in a vaccine [2, 4, 5] . Thus, a major component of the vaccine development effort is the isolation and characterization of broadly neutralizing antibodies (bNAbs) in order to decipher the molecular characteristics, and eventually the ontogeny, of such a response [6] [7] [8] [9] .
Some bNAbs have been shown to confer sterilizing protection via passive immunoprophylaxis in animal challenge models [10] [11] [12] [13] [14] , and delay virologic rebound during treatment interruption in humans [15] . Furthermore, proof-of-concept studies in mice and macaques have demonstrated protection when bNAbs are expressed using vector-mediated gene transfer, raising the possibility that difficulties in immunogen design might be bypassed by the induction of durable immunity through gene therapy approaches [16] [17] [18] [19] . Given the substantial costs, risks, and regulatory issues involved in deploying this technology in human clinical trials, let alone eventually treating the hundreds of millions of people at risk for HIV acquisition, selection of the most broadly active and potent antibody or combination of antibodies is a vital prerequisite.
To quantify the degree of 'broadness' of the available bNAbs, studies to date have generally sampled a single or a very small number of viral isolates from a large number of patients [20] [21] [22] . However, it is important to note that the patients from whom these bNAbs were originally isolated do not fully control their own virus, and circulating quasispecies variants from one patient studied longitudinally show evidence of ongoing escape from the contemporaneous antibody repertoire [23] . Thus, it is important to determine the frequency of pre-existing minor variants resistant to the relevant bNAbs before they are deployed within a population, as such variants could result in treatment failure. Unfortunately, due to the complexity of the targeted epitopes and our incomplete knowledge of the envelope trimer structure, robust sequence-based resistance screening is currently impossible. Consequently, direct phenotypic testing of multiple primary isolates from both chronically and newly infected patients is required to characterize the patterns of baseline resistance present in the target population.
For much of the past two decades, there have been only four bNAbs in our armamentarium, all isolated from subtype B-infected patients: 4E10, 2F5, b12, and 2G12 [24] [25] [26] [27] . These antibodies have limited activity in non-B subtypes, with the exception of 4E10, which neutralizes most strains with low to moderate potency [28] . These limitations greatly diminish their usefulness in the epicenter of the pandemic (sub-Saharan Africa) where subtype C dominates. However, since 2009, there has been a rapid increase in the pace of identification of anti-HIV bNAbs [20, 22, [29] [30] [31] , resulting in a much needed bolus of potent new antibodies and essentially reversing the problem; now they are being developed faster and in greater numbers than can be feasibly put into clinical trials.
Many of these antibodies target two highly conserved sites on gp120: either a quaternary epitope including V1-V3 (PG series) or the CD4-binding site (VRC, NIH45, 3BNC, and 8ANC series), and have good activity against nonsubtype B viruses [29] [30] [31] . Given that antibodies against these two sites do not interfere with each other [21] , but antibodies to each individual site compete amongst themselves [30, 31] , we sought to determine what combination of available bNAbs had the highest potency and broadest coverage against a large panel of primary isolates from subtype C-infected women and their infants. Due to the relatively large number of molecular envelope clones available from each transmission pair (median of 10 unique envelopes per pair), this cohort allowed us to look at coverage and neutralization sensitivity at greater depth than has been previously reported.
Our study found the combination of PG16 and the engineered variant NIH45-46 G54W was the broadest and most potent, neutralizing all tested variants from the greatest number of transmission pairs, and a striking 96% of recently infected infants. Since vector-mediated gene transfer obviates the need to elicit a 'natural' antibody response, our data strongly support the use of engineered variants like NIH45-46 G54W , or even more extensively modified antibodies, as the basis for future human clinical trials.
Materials and methods

Patient population
All women were participants in the Zambia Exclusive Breastfeeding Study (ZEBS); a clinical trial for the prevention of mother-to-child transmission (MTCT) that has been previously described [32] . Briefly, antiretroviral drug-naive, pregnant, HIV-infected women were prospectively enrolled and maternal blood was collected at study entry; and maternal blood and breast milk were collected at specified intervals following delivery. Infant blood was collected at 3 months after delivery. Antiretroviral drug exposure during the study was limited to single-dose peripartum nevirapine, given in accordance with Zambian government guidelines at the time. No patients had been treated with bNAbs or HIV Immune Globulin (HIVIG). Twenty-three mother/ infant transmission pairs were included in the analyses.
Envelope cloning
Molecular cloning of full-length HIV gp160 genes has been described previously [33] . Envelopes were obtained from breast milk cells, plasma RNA, and PBMC DNA; previous work has shown a lack of genetic compartmentalization for these sample types [33] . All envelope sequences were screened for re-sampling, recombination, inter-patient, and reference strain contamination as described in the preceding reference. Phylogenetic trees were constructed using DIVEIN [34] under the GTRþIþG maximum likelihood model and visualized/edited in FigTree (http://tree.bio.ed.ac.uk/ software/figtree/). 
Cells and antibodies
Virus neutralization assay
Neutralization experiments were performed and IC 50 values calculated as previously described [35] . In summary, pseudotype virus (2000 infectious units) produced in 293T/17 cells by co-transfection of an env-deficient backbone and env-expression plasmid, were preincubated 1 h with serial 5Â dilutions of antibody, then added to TZM-bl cells and incubated for 48 h before luciferase activity was measured [35] .
Data analysis
Every IC 50 analyzed is the mean of at least two independent experiments with 3Â or less variation. Fold-change in potency by IC 50 ratio was calculated in Excel (Microsoft, Seattle, Washington, USA), with all IC 50 values at least 10 mg/ml censored at 10. Resistance was defined as an IC 50 at least 10 mg/ml prior to data collection. For per-patient and per-pair coverage we chose the conservative analytical approach of assigning to each patient (or pair) the highest IC 50 value of any clone from that patient (or pair) for each antibody. Every data point from a patient was treated independently; thus if two unique clones from a single patient were resistant to two different antibodies, that patient was scored as resistant to both. Coverage was defined as the percentage of patient-pairs for which every clone was sensitive (IC 50 <10 mg/ml) to a given antibody.
To compare potency of different antibodies, IC 50 ratios were calculated for all 227 clones individually for each combination of interest. To estimate the effect of reduced sampling depth on coverage, we set the detected frequency of resistant variants within a given patient-pair as the true frequency, and then calculated the cumulative probability of sampling only sensitive clones from that pair at a given depth. These probabilities were then summed across all 23 pairs and used to construct coverage curves for each antibody.
Results
Clinical and molecular characteristics of study cohort Twenty-three mother-infant pairs were included in this study; 22 were infected with subtype C HIV-1 and one (Subj. 8) was infected with subtype G. Median maternal plasma HIV RNA was 171 931 copies/ml and median maternal CD4 cell count was 146 cells/ml. Infant viral RNA load and CD4 percentages were not determined. A total of 227 full-length gp160 s were tested for neutralization sensitivity, with a median of seven maternal and three infant clones per pair (Table 1) . Envelope sequences from each chronically infected woman and her infant formed a distinct monophyletic cluster ( Fig. 1 ).
Loop-directed antibodies PG9 and PG16 have similar breadth but PG16 is more potent PG9 and PG16, the first of the 'second-generation' monoclonal antibodies described, are somatic variants that target distinct but partially overlapping quaternary epitopes on gp120 that include the V1, V2, and V3 loops [30, 36, 37] . As expected, we observed a high degree of concordance between these two bNAbs, with only 2.2% (5/227) of isolates resistant to one but sensitive to the other. When mothers and their infected infants were analyzed separately, we found PG9 neutralized all viruses from 72% (33/46) of patients (i.e. 72% coverage), whereas PG16 had 67% (31/46) coverage of our cohort ( Table 2) . When results were pooled by transmission-pair (mother and infant considered together) we observed 100% concordance with 43% (10/23) of pairs harboring resistance to both antibodies and the remaining 57% (13/23) of pairs harboring virus fully sensitive to both (Figs 2a,b and 3a, b). PG16 was approximately 4.4Â more potent than PG9 by IC 50 ratio (data not shown).
Potent CD4 binding-site antibodies VRC01, NIH45-46, and 3BNC117 display similar breadth and potency VRC01, VRC03, and NIH45-46 (4546) were isolated from the same patient using different sets of PCR primers, and target the CD4 binding site (CD4bs) on gp120 [29, 31] . 8ANC195 and 3BNC117, also targeting the CD4bs, were isolated from two additional patients [29] . VRC03 and 8ANC195, both of which have been described as having limited breadth and potency relative to the other CD4bs bNAbs [29, 31] , also had minimal activity in our cohort and were excluded from further analysis (data not shown).
In the per-patient analysis, VRC01 had complete coverage (neutralizing all envelopes from a given patient) of 65% (30/46) of patients, 4546 had 50% (23/46) coverage, and 3BNC117 had 57% (26/46) coverage (Table 2) . VRC01, 4546, and 3BNC117 also had similar breadth in the more conservative per-pair analysis, with overall coverage of 48% (VRC01), 35% (4546), and 39% (3BNC117) (Figs 2c-e and 3a,b ). There was also significant overlap, with most transmission-pairs that harbored virus resistant to one CD4bs bNAb also harboring variants resistant to the other two, though not in every case. On a per-clone basis, all three bNAbs were similarly potent, with median IC 50 ratios of 0.85-1.00 (data not shown).
Engineered bNAb NIH45-46 G54W has significantly improved breadth and potency relative to other CD4bs antibodies NIH45-46 G54W (4546W) is the first example of structurebased engineering of a neutralizing antibody. It is a variant of NIH45-46 designed to improve breadth and potency by inserting a tryptophan into the 'Phe43 pocket', a critical site involved in gp120 binding to CD4. The design and binding properties of 4546W have been described [22] . The glycine-to-tryptophan substitution increased coverage of this antibody relative to the parental variant, from
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Since we had data on a large number of early transmitted isolates, we examined the baseline coverage of these antibodies both alone and in combination to simulate a prophylactic intervention. Against all 68 early transmitted isolates (from 23 transmission pairs) we found antibody coverage was within a similar range (65-78%) for all bNAbs tested (Fig. 3c) . The combination of PG16 with either VRC01 or 4546Woffered the best coverage, with all variants from 96% of infants (22/23) susceptible to at least one bNAb. Both 4546 and 3BNC117 achieved 87% coverage in conjunction with PG16 ( Fig. 3e ). Considering the median IC 50 ratios of just the early-transmitted isolates, 4546W was approximately 2.1Â more potent than parental 4546 and approximately 5Â more potent than VRC01.
Minor variants resistant to NIH45-46 G54W are uncommon and associated with resistance to other CD4bs bNAbs The ability to detect pre-existing minor variants that harbor resistance is a critical factor in the success or failure of treatment with existing antiretroviral drugs including entry inhibitors such as maraviroc [38] [39] [40] . Thus, whereas broad sampling at shallow depth gives a good estimate of the prevalence of dominant resistance, it cannot determine the frequency of minor variants that could, under selection, rapidly outgrow, and compromise the effectiveness of an inhibitor. Whereas we do not consider a median sampling depth of 10 clones per pair to be exhaustive, this cohort does give us the opportunity to probe for minority variants within quasispecies resistant to these new antibodies in a way that has not been previously described.
When we set a 'low frequency' cut-off of 20% or less, we identified only three pairs harboring minor variants resistant to 4546, 4546W, four with minor variants resistant to 3BNC117, and six pairs harboring a minority population resistant to VRC01. Importantly, the presence of a minor population resistant to 4546W was associated with low and/or high frequency resistance to at least two of the other CD4bs antibodies. In contrast, there were several cases where minor variants resistant to 4546, 3BNC117, or VRC01 were detected in the absence of resistance to multiple other CD4bs antibodies ( Fig. 2c-f ).
High intra-pair and intra-patient variation and its effect on the relationship between sampling depth and coverage
We observed a surprising degree of intra-pair variation in susceptibility with all tested antibodies, with a median fold difference of 14.7-38.1Â between the most resistant and most sensitive clone within a pair (data not shown).
In one example (Subj. 13) sampling of 10 unique clones identified a 265-fold difference in IC 50 for PG9, without detecting outright resistance (range 0.0024-0.6361 mg/ml) ( Fig. 2a) .
Given the high degree of intra-patient variation, we next estimated the probability of detecting at least one resistant variant for each transmission pair over a range of sampling depths and constructed a plot showing estimated coverage with a sampling depth ranging from 1 to 10 clones per pair (Fig. 3f ). Coverage estimates produced by sampling only a single clone per pair ranged from 62-87%, with PG9, PG16, and 4546W scoring above 80% and VRC01 scoring 79%. These coverage estimates are at least 20% higher than our actual results at a median of 10 clones per pair, which are still likely to be overestimates.
Discussion
We found that loop-targeted antibodies PG9 and PG16 neutralized envelopes from our cohort of MTCT pairs with 57% coverage in our conservative per-patient analysis. Resistance to one PG antibody was highly correlated with resistance to the other, which is expected given that they are somatic variants targeting distinct but overlapping epitopes. PG16 neutralized viruses from this cohort more potently than PG9 by almost half a log 10 , suggesting it would be the better choice for initial clinical studies, at least for prevention of MTCT (pMTCT) in a population predominantly infected with subtype C.
Qualitatively, the battery of CD4-binding site antibodies fell into three categories: VRC03 and 8ANC195 performed poorly; VRC01, 3BNC117, and 4546 performed moderately well and neutralized with similar potencies; and 4546W had the broadest coverage and highest neutralization potency of any CD4bs antibody in our study. Additionally, minor variants resistant to 4546W were uncommon, and patients harboring 4546W-resistant envelopes typically harbored variants resistant to the other CD4bs antibodies as well. A caveat is that our median sampling depth of 10 clones per transmission pair, whereas more extensive than other studies, is not definitive, and likely underestimates the true prevalence of pre-existing resistance to these reagents. Our data argue in favor of using 4546W (or a further modified variant) for future clinical studies, since resistance to 4546W appears to be rare and associated with resistance to the CD4bs antibody class in general. Studies of additional CD4 binding site antibodies would be required to confirm this characteristic of 4546W. This observation is compatible with a more conserved mechanism of neutralization for 4546W (via the 'Phe43 pocket') and a higher genetic barrier to resistance, but our study did not directly address these issues.
Our data indicate that the combination of 4546W and PG16 is likely to be the most effective pair of antibodies for pMTCT, and perhaps preventive studies in general in subtype C-infected populations. This combination has the greatest breadth in both the conservative per-pair analysis and the restricted subset of early transmitted isolates (neutralizing all tested variants from 22/23 infected infants). Moreover, these antibodies had the highest neutralization potency (measured by IC 50 ) of all the antibodies we tested from their respective classes. Several other CD4bs antibodies (VRC01, 3BNC117, and 4546) also had relatively broad coverage of the early transmitted isolates, but at 2-5Â reduced potency compared to 4546W.
Women in our study were HIV-positive at the time of enrollment and seroconversion dates were not available. Their low CD4 cell counts suggest late-stage chronic infection, which is generally associated with greater genetic diversity, likely contributing to the frequent detection of pre-existing bNAb-resistant variants. Envelopes from the 23 epidemiologically linked infants exhibited the restricted genetic diversity typical of recent infection, and were better covered by the tested bNAbs. The generalizability of our findings to other forms of transmission is unclear and warrants further investigation.
The study represents, to our knowledge, the deepest sampling of HIV-infected persons in the context of secondgeneration bNAbs. Our data are qualitatively similar to a recent study [21] that sampled approximately 200 patients from multiple clades at a median depth of 1 clone per patient and found the combination of a loop-targeted (PG series) and CD4bs antibody (VRC01, VRC-PG04) had very good coverage of a diverse panel of global strains, though that study did not include the 4546W variant for comparison. It is important to emphasize here the heterogeneity of our data and the effect of sampling depth on coverage estimates that we observed. Antibody susceptibility within some patient-pairs differed by several orders of magnitude, which indicates substantial phenotypic variation exists even within patients described by our analyses as fully sensitive. At a sampling depth of 1 clone per pair, our results would be very similar to that study [21] , with VRC01, PG9 and PG16 all achieving coverage in the approximately 75-85% range at an IC 50 less than 10 mg/ml, whereas our actual median sampling depth of 10 clones identified resistant variants in an additional 25-30% of patients. Given that even minor resistant variants in the 2% prevalence range have been implicated in virologic failure with other therapeutic agents, including the entry inhibitor maraviroc [39, 40] , our data encourage tempering of expectations. HIV's propensity for rapid escape, due to the exceptional plasticity of its envelope, suggests modified reagents that raise the genetic barrier to resistance may have a disproportionate advantage against diverse quasispecies. Our current inability to screen for bNAb resistance using high-throughput genetic methods requires isolates to be phenotypically characterized. Thus, it will be important to pair studies like this one with broader surveys such as the one referenced above [21] .
Considering the difficulty the field has experienced in immunogen design for the induction of broadly neutralizing antibodies, and the consequent interest in using a gene therapy-based approach to bypass the immune system, we see no reason to constrain future proof-of-principle immunotherapy or immunoprophylaxis studies to 'naturally' occurring antibodies only. In this context, our data indicate that engineered antibody 4546W is the most broad and potent CD4 binding site antibody currently available in the setting of HIV-1 subtype C pMTCT, and it, or an even more potent variant, should be considered for inclusion in any future clinical trial.
